Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
Can-Fite Selected to Deliver Late-Breaking Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases
COVID-19 Forces One of the Biggest Surges in Technology Investment in History, Finds World’s Largest Technology Leadership Survey
12:00am, Tuesday, 22'nd Sep 2020
COVID-19 forces one of the biggest surges in tech investment in history, finds Harvey Nash/KPMG CIO Survey.
U.S. IPO Weekly Recap: Snowflake's IPO Breaks Records In A Diverse 15-IPO Week
01:54pm, Saturday, 19'th Sep 2020
In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion. Snowflake took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two d
Résultats financiers du 1er semestre 2020 et point sur l'activité
08:00pm, Wednesday, 16'th Sep 2020
Trésorerie et équivalents de trésorerie à 52,3 M€ au 30 juin 2020
Succès de l'introduction en bourse sur le Nasdaq Global Market, avec une levée de 107,7 M$ (94,9 M€) prolongeant la vis
Résultats financiers du 1er semestre 2020 et point sur l’activité
12:00am, Wednesday, 16'th Sep 2020
Trésorerie et équivalents de trésorerie à 52,3 M€ au 30 juin 2020Succès de l'introduction en bourse sur le Nasdaq Global Market, avec une levée de 107,7...
Poxel publie ses résultats financiers du premier semestre 2020 et dresse un bilan de ses activités
12:00am, Tuesday, 15'th Sep 2020
Regulatory News: POXEL SA (Paris:POXEL) (Euronext : POXEL — FR0012432516), société biopharmaceutique spécialisée dans le développement de traitements
Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for NASH
IPO Update: Metacrine Seeks $85 Million U.S. IPO
02:58pm, Friday, 11'th Sep 2020
Metacrine has filed to raise $85 million in an IPO of its common stock. The firm is developing treatments for NASH, a liver disease whose prevalence is increasing rapidly.
Enanta Pharmaceuticals Presents New Data from its Hepatitis B and Non-Alcoholic Steatohepatitis Programs at the Digital International Liver Congress
Can-Fite Reports Second Quarter 2020 Financial Results & Provides Clinical Update
12:00am, Thursday, 27'th Aug 2020
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that addre
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced today that on Friday, August 28, 2020 at the Digital International Liver Congress™ 2020, European
Gilead Sciences, Inc. (Nasdaq: GILD) announced the presentation of more than 40 abstracts reflecting the breadth of research from the company’s progra
Global Non-Alcoholic Steatohepatitis (NASH) Pipeline Review, H2 2020 - ResearchAndMarkets.com
12:00am, Monday, 24'th Aug 2020
The
Intercept to Present New NASH and PBC Data at the Digital International Liver Congress™ 2020
12:00pm, Friday, 21'st Aug 2020
New analyses of the interim analysis data from the Phase 3 REGENERATE study describe the benefit of obeticholic acid (OCA) on noninvasive measures of liver
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
12:00am, Wednesday, 19'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
